Beshoy Yanny
Associate Director, Hepatology , Medicine
School of Medicine
School of Medicine
M.D.
University of California, Irvine
3800 Chapman Ave Ste # 6800
Orange, CA 92868
3800 Chapman Ave Ste # 6800
Orange, CA 92868
Publications
2015
1. Yanny, B., & Sahota, A. (2015). Lower Effectiveness of Sofosbuvir Based HCV Regimens in
Treatment Experienced Elderly Patients With Genotype 1 in a Community-Based Setting: 2201.
Official journal of the American College of Gastroenterology| ACG, 110, S915.
2. Yanny, B., & Sahota, A. (2015). Effectiveness of Direct-Acting, Antiviral, Agent-Based HCV
Regimens in Patients Over 75 Years of Age in a Community-Based Setting: 2189. Official journal
of the American College of Gastroenterology| ACG, 110, S910-S911.
3. Yanny, B. T., & Sahota, A. K. (2015, October). Efficacy and Adverse Event Profile of Sofosbuvir
Based Hepatitis C Virus (HCV) Treatment Regimens in the Elderly in a Community Based Setting.
In HEPATOLOGY (Vol. 62, pp. 760A-761A). Hoboken, NJ: Wiley-Blackwell.
4. Beshoy, Y., Nneji, J., & Buxbaum, J. (2015). A case of the hiccups in the setting of colonic ulcers.
Gastroenterology, 148(1), e8-e9.
2016
5. Yanny, B., & Sahota, A. (2016). Efficacy and Adverse Event Profile of an Eight Week LedipasvirSofosbuvir Based Hepatitis C Virus (HCV) Treatment Regimen in Human Immune Deficiency
Virus (HIV) Patients in a Community Based Setting: 2500. Official journal of the American
College of Gastroenterology| ACG, 111, S1272.
6. Yanny, B., & Sahota, A. (2016). Efficacy and Adverse Event Profile of an Eight Week LedipasvirSofosbuvir Based Hepatitis C Virus (HCV) Treatment Regimen in Human Immune Deficiency
Virus (HIV) Patients in a Community Based Setting: 2500. Official journal of the American
College of Gastroenterology| ACG, 111, S1272.
2017
7. Louie, V., Latt, N. L., Gharibian, D., Sahota, A., Yanny, B. T., Mittal, R., ... & Cheetham, T. C.
(2017). Real-world experiences with a direct-acting antiviral agent for patients with hepatitis C
virus infection. The Permanente Journal, 21, 16-096.
8. Latt, N. L., Yanny, B. T., Gharibian, D., Gevorkyan, R., & Sahota, A. K. (2017). Eight-week
ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with
hepatitis C virus-RNA< 6 million: Single center, real world effectiveness and safety. World
Journal of Gastroenterology, 23(26), 4759.
9. Latt, N. L., Yanny, B. T., Gharibian, D., Gevorkyan, R., & Sahota, A. K. (2017). Eight-week
ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with
hepatitis C virus-RNA< 6 million: Single center, real world effectiveness and safety. World
Journal of Gastroenterology, 26.
Yanny, Beshoy
Updated: July 2021
6
10. Latt, N. L., Yanny, B. T., Gharibian, D., Gevorkyan, R., & Sahota, A. K. SVR of 8-Weeks
Ledipasvir/Sofosbuvir Therapy.
11. Yanny, B., & Sahota, A. (2017). Reactivation of hepatitis B virus among patients treated with
ledipasvir-sofosbuvir (LDV/SOF) for hepatitis C virus infection in a community based setting.
Gastroenterology, 152(5), S1059.
12. Latt, N. L., Mousa, O., Aqel, B., Leise, M. D., Keaveny, A., & Pungpapong, S. (2017). Impact of
Hepatitis C Treatment on Survival Outcomes Among Liver Transplant Recipients with Recurrent
Infection in the Era of Direct-Acting Anti-Viral Agents. Gastroenterology, 152(5), S1058.
2018
13. Yanny, B. T., Latt, N. L., Saab, S., Han, S., Choi, G., Kramer, J., & Sahota, A. K. (2018). Risk of
hepatitis B virus reactivation among patients treated with ledipasvir-sofosbuvir for hepatitis C virus
infection. Journal of Clinical Gastroenterology, 52(10), 908-912.
14. Yanny, B., Saab, S., Durazo, F., Latt, N., Mitry, A., Mikhail, M. M., ... & Sahota, A. (2018). EightWeek Hepatitis C Treatment with New Direct Acting Antivirals Has a Better Safety Profile While
Being Effective in the Treatment-Naïve Geriatric Population Without Liver Cirrhosis and Hepatitis
C Virus-RNA< 6 Million IU/mL. Digestive Diseases and Sciences, 63(12), 3480-3486.
15. Saab, S., Ahn, T., McDaniel, T., Yanny, B., & Tong, M. J. (2018). Economic comparison of
serologic and molecular screening strategies for hepatitis C virus. Gastroenterology & Hepatology,
14(8), 459.
16. Yanny, B., Durazo, F. A., Aziz, A., Busuttil, R., & Kaldas, F. M. (2018, October). Largest Series
Exploring Implications of Gamma-Glutamyl Transferase Elevation in Post Liver Transplant
Recipients, an Analysis of 511 Consecutive Patients. In HEPATOLOGY (Vol. 68, pp. 702A-703A).
Hoboken, NJ: Wiley.
2019
17. Yanny, B., Winters, A., Boutros, S., & Saab, S. (2019). Hepatic encephalopathy challenges,
burden, and diagnostic and therapeutic approach. Clinics in Liver Disease, 23(4), 607-623.
18. Yanny, B., Konyn, P., Najarian, L. M., Mitry, A., & Saab, S. (2019). Management approaches to
hepatitis B virus vaccination nonresponse. Gastroenterology & Hepatology, 15(2), 93.
19. Abdelaal, R., Yanny, B., & El Kabany, M. (2019). HBV/HCV Coinfection in the Era of HCVDAAs. Clinics in liver disease, 23(3), 463-472.
20. Hanna, R. M., Hasnain, H., Abdelnour, L., Yanny, B., & Burwick, R. M. (2019). Atypical
hemolytic uremic syndrome in a patient with protein-losing enteropathy. Journal of International
Medical Research, 47(8), 4027-4032.
21. Hanna, R. M., Yanny, B., Arman, F., Barsoum, M., Mikhail, M., Al Baghdadi, M., ... & Saab, S.
(2019). Everolimus worsening chronic proteinuria in patient with diabetic nephropathy post liver
transplantation. Saudi Journal of Kidney Diseases and Transplantation, 30(4), 989-994.
22. Hanna, R. M., Merin, N., Burwick, R. M., Abdelnour, L., Selamet, U., Yanny, B., ... & Kurtz, I.
(2019). Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with
inflammatory bowel disease. Thrombosis Journal, 17(1), 18.
23. Grewal, J., Doan, A., Hong, A. S., Amin, A., Scapa, J. V., Hanna, R., ... & Yanny, B. (2019).
Drug-induced autoimmune hepatitis from hydralazine leading to acute liver failure and liver
transplantation. ACG case reports journal, 6(10), e00252.
Yanny, Beshoy
Updated: July 2021
7
24. Belachew, W., Hanna, R. M., & Yanny, B. (2019). Albumin in Patients with Cirrhosis, When Does
it Help?. Proceedings of UCLA Health, 23(1).
25. Yanny, B., El Kabany, M., & Saab, S. (2019, October). Decreased hepatitis B vaccine efficacy in
obese individuals and approaches to previously immunized non-responders. In HEPATOLOGY
(Vol. 70, pp. 594A-594A). Hoboken, NJ: Wiley.
26. Yanny, B., El Kabany, M., & Saab, S. (2019, October). EIGHT WEEK HEPATITIS C VIRUS
TREATMENT WITH SOBOSFOVIR BASED REGIMEN IS EFFECTIVE IN PEOPLE WHO
INJECT DRUGS WITHIN 6 MONTHS OF TREATMENT DESPITE NON-ADHERENCE TO
LAB AND CLINIC FOLLOW-UP. In HEPATOLOGY (Vol. 70, pp. 956A-957A). Hoboken, NJ:
Wiley.
27. Saab, S. (2019). Portal Hypertension: Portal Hypertension (Vol. 23, No. 4). Elsevier Health
Sciences.
28. Hassanein, T. I. (2019). Hepatitis B Virus, An Issue of Clinics in Liver Disease (Vol. 23, No. 2).
Elsevier Health Sciences.
2020
29. Yanny, B., Boutros, S., Saleh, F., & Saab, S. (2020). Liver transplantation for alcoholic hepatitis:
update. Current Opinion in Gastroenterology, 36(3), 157-163.
30. Yanny, B., Pham, N. V., Saleh, H., & Saab, S. (2020). Approaches to assessing burden in
caregivers of patients with cirrhosis. Journal of Clinical and Translational Hepatology, 8(2), 127.
31. Yanny, B., Viramontes, M., Najarian, L. M., Challita, Y., & Saab, S. (2020). Ethnic perception of
obesity in fatty liver disease. Digestive Medicine Research, 3.
32. Grewal, J., Lenhart, A., Doan, A., Walter, K., Wang, Y., & Yanny, B. (2020). Su1664
POSITIVELY WRONG: NON-ALCOHOLIC STEATOHEPATITIS AND DRUG INDUCED
LIVER INJURY ARE ASSOCIATED WITH AUTOANTIBODY POSITIVITY IN PATIENTS
WITHOUT OTHER AUTOIMMUNE DISEASES IN A LARGE ACADEMIC SETTING.
Gastroenterology, 158(6), S-1379.
33. Lenhart, A., Grewal, J., Wang, Y., Kang, S., & Yanny, B. (2020). Sa1547 CHRONIC HEPATITIS
E POST-ORGAN TRANSPLANTATION CAN MIMIC REJECTION AND LEAD TO
CIRRHOSIS: A CASE SERIES EXPLORING PATIENT DEMOGRAPHICS, TREATMENT,
AND OUTCOMES. Gastroenterology, 158(6), S-1329.
34. Weiss, G. A. (2020). Diagnosis and Management of Gluten-Associated Disorders.
35. Yanny, B., Grewal, J. K., & Vaswani, V. K. (2020). Celiac Disease and the Liver. Diagnosis and
Management of Gluten-Associated Disorders: A Clinical Casebook, 27-40.
2022
36. Xu, H., & Yanny, B. (2022). Primary Biliary Cholangitis: A Review. Gene Expression, 21(2), 45-
50.
Yanny, Beshoy
Updated: July 2021
8
2023
37. Yanny, B., Alkhero, M., Alani, M., Stenberg, D., Saharan, A., & Saab, S. (2023). Post-COVID-19
cholangiopathy: a systematic review. Journal of Clinical and Experimental Hepatology, 13(3),
489-499.
38. Farooq, M., Irania, S., Bahdi, F., Yanny, B., & Issa, D. (2023). S2227 Bile Cast Syndrome in a
Young Female Following Severe COVID-19 Infection. Official journal of the American College of
Gastroenterology| ACG, 118(10S), S1596.
39. Nguyen, M., Yanny, B. T., Truong, T. L., Zhao, H., & Hanna, R. (2023). Tolvaptan-induced
isolated elevation of bilirubin in a patient with Gilbert syndrome. SAGE Open Medical Case
Reports, 11, 2050313X231169841.
40. Coe, C. L., Prause, N., Benhammou, J. N., Singh, J., Shetty, A., Trivedi, H., ... & Patel, A. A.
(2023, October). PREVALENCE AND PREDICTORS OF PROBLEMATIC ALCOHOL USE
AMONG TRANSPLANT HEPATOLOGISTS. In HEPATOLOGY (Vol. 78, pp. S1720-S1721).
Philadelphia, PA: Lippincott Williams & Wilkins.
2024
41. Singh, J., Ibrahim, B., Jackson, N. J., Khalil, H., Valenzuela, J., Yanny, B., & Saab, S. (2024).
Lower FIB-4 threshold in patients with diabetes improves diagnostic accuracy of the test in a
Hispanic population. Translational Gastroenterology and Hepatology, 9, 16.
42. Windheim, J., Yoon, S., Hahn, K., Klomhaus, A., Hixson, R., Wen, R., ... & Barjaktarevic, I.
(2024). THE ASSOCIATION OF ALPHA-1 ANTITRYPSIN LEVELS WITH LIVER
FUNCTION, AND THE CHANGE IN ALPHA-1 ANTITRYPSIN LEVELS
LONGITUDINALLY IN CIRRHOTIC PATIENTS. Chest, 166(4), A4893.
2025
43. Coe, C., Prause, N., Benhammou, J. N., Singh, J., Shetty, A., Trivedi, H. D., ... & Patel, A. A.
(2025). One in 4 transplant hepatologists in the United States screens positive for unhealthy
alcohol use. Hepatology Communications, 9(11), e0819.
1. Yanny, B., & Sahota, A. (2015). Lower Effectiveness of Sofosbuvir Based HCV Regimens in
Treatment Experienced Elderly Patients With Genotype 1 in a Community-Based Setting: 2201.
Official journal of the American College of Gastroenterology| ACG, 110, S915.
2. Yanny, B., & Sahota, A. (2015). Effectiveness of Direct-Acting, Antiviral, Agent-Based HCV
Regimens in Patients Over 75 Years of Age in a Community-Based Setting: 2189. Official journal
of the American College of Gastroenterology| ACG, 110, S910-S911.
3. Yanny, B. T., & Sahota, A. K. (2015, October). Efficacy and Adverse Event Profile of Sofosbuvir
Based Hepatitis C Virus (HCV) Treatment Regimens in the Elderly in a Community Based Setting.
In HEPATOLOGY (Vol. 62, pp. 760A-761A). Hoboken, NJ: Wiley-Blackwell.
4. Beshoy, Y., Nneji, J., & Buxbaum, J. (2015). A case of the hiccups in the setting of colonic ulcers.
Gastroenterology, 148(1), e8-e9.
2016
5. Yanny, B., & Sahota, A. (2016). Efficacy and Adverse Event Profile of an Eight Week LedipasvirSofosbuvir Based Hepatitis C Virus (HCV) Treatment Regimen in Human Immune Deficiency
Virus (HIV) Patients in a Community Based Setting: 2500. Official journal of the American
College of Gastroenterology| ACG, 111, S1272.
6. Yanny, B., & Sahota, A. (2016). Efficacy and Adverse Event Profile of an Eight Week LedipasvirSofosbuvir Based Hepatitis C Virus (HCV) Treatment Regimen in Human Immune Deficiency
Virus (HIV) Patients in a Community Based Setting: 2500. Official journal of the American
College of Gastroenterology| ACG, 111, S1272.
2017
7. Louie, V., Latt, N. L., Gharibian, D., Sahota, A., Yanny, B. T., Mittal, R., ... & Cheetham, T. C.
(2017). Real-world experiences with a direct-acting antiviral agent for patients with hepatitis C
virus infection. The Permanente Journal, 21, 16-096.
8. Latt, N. L., Yanny, B. T., Gharibian, D., Gevorkyan, R., & Sahota, A. K. (2017). Eight-week
ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with
hepatitis C virus-RNA< 6 million: Single center, real world effectiveness and safety. World
Journal of Gastroenterology, 23(26), 4759.
9. Latt, N. L., Yanny, B. T., Gharibian, D., Gevorkyan, R., & Sahota, A. K. (2017). Eight-week
ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with
hepatitis C virus-RNA< 6 million: Single center, real world effectiveness and safety. World
Journal of Gastroenterology, 26.
Yanny, Beshoy
Updated: July 2021
6
10. Latt, N. L., Yanny, B. T., Gharibian, D., Gevorkyan, R., & Sahota, A. K. SVR of 8-Weeks
Ledipasvir/Sofosbuvir Therapy.
11. Yanny, B., & Sahota, A. (2017). Reactivation of hepatitis B virus among patients treated with
ledipasvir-sofosbuvir (LDV/SOF) for hepatitis C virus infection in a community based setting.
Gastroenterology, 152(5), S1059.
12. Latt, N. L., Mousa, O., Aqel, B., Leise, M. D., Keaveny, A., & Pungpapong, S. (2017). Impact of
Hepatitis C Treatment on Survival Outcomes Among Liver Transplant Recipients with Recurrent
Infection in the Era of Direct-Acting Anti-Viral Agents. Gastroenterology, 152(5), S1058.
2018
13. Yanny, B. T., Latt, N. L., Saab, S., Han, S., Choi, G., Kramer, J., & Sahota, A. K. (2018). Risk of
hepatitis B virus reactivation among patients treated with ledipasvir-sofosbuvir for hepatitis C virus
infection. Journal of Clinical Gastroenterology, 52(10), 908-912.
14. Yanny, B., Saab, S., Durazo, F., Latt, N., Mitry, A., Mikhail, M. M., ... & Sahota, A. (2018). EightWeek Hepatitis C Treatment with New Direct Acting Antivirals Has a Better Safety Profile While
Being Effective in the Treatment-Naïve Geriatric Population Without Liver Cirrhosis and Hepatitis
C Virus-RNA< 6 Million IU/mL. Digestive Diseases and Sciences, 63(12), 3480-3486.
15. Saab, S., Ahn, T., McDaniel, T., Yanny, B., & Tong, M. J. (2018). Economic comparison of
serologic and molecular screening strategies for hepatitis C virus. Gastroenterology & Hepatology,
14(8), 459.
16. Yanny, B., Durazo, F. A., Aziz, A., Busuttil, R., & Kaldas, F. M. (2018, October). Largest Series
Exploring Implications of Gamma-Glutamyl Transferase Elevation in Post Liver Transplant
Recipients, an Analysis of 511 Consecutive Patients. In HEPATOLOGY (Vol. 68, pp. 702A-703A).
Hoboken, NJ: Wiley.
2019
17. Yanny, B., Winters, A., Boutros, S., & Saab, S. (2019). Hepatic encephalopathy challenges,
burden, and diagnostic and therapeutic approach. Clinics in Liver Disease, 23(4), 607-623.
18. Yanny, B., Konyn, P., Najarian, L. M., Mitry, A., & Saab, S. (2019). Management approaches to
hepatitis B virus vaccination nonresponse. Gastroenterology & Hepatology, 15(2), 93.
19. Abdelaal, R., Yanny, B., & El Kabany, M. (2019). HBV/HCV Coinfection in the Era of HCVDAAs. Clinics in liver disease, 23(3), 463-472.
20. Hanna, R. M., Hasnain, H., Abdelnour, L., Yanny, B., & Burwick, R. M. (2019). Atypical
hemolytic uremic syndrome in a patient with protein-losing enteropathy. Journal of International
Medical Research, 47(8), 4027-4032.
21. Hanna, R. M., Yanny, B., Arman, F., Barsoum, M., Mikhail, M., Al Baghdadi, M., ... & Saab, S.
(2019). Everolimus worsening chronic proteinuria in patient with diabetic nephropathy post liver
transplantation. Saudi Journal of Kidney Diseases and Transplantation, 30(4), 989-994.
22. Hanna, R. M., Merin, N., Burwick, R. M., Abdelnour, L., Selamet, U., Yanny, B., ... & Kurtz, I.
(2019). Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with
inflammatory bowel disease. Thrombosis Journal, 17(1), 18.
23. Grewal, J., Doan, A., Hong, A. S., Amin, A., Scapa, J. V., Hanna, R., ... & Yanny, B. (2019).
Drug-induced autoimmune hepatitis from hydralazine leading to acute liver failure and liver
transplantation. ACG case reports journal, 6(10), e00252.
Yanny, Beshoy
Updated: July 2021
7
24. Belachew, W., Hanna, R. M., & Yanny, B. (2019). Albumin in Patients with Cirrhosis, When Does
it Help?. Proceedings of UCLA Health, 23(1).
25. Yanny, B., El Kabany, M., & Saab, S. (2019, October). Decreased hepatitis B vaccine efficacy in
obese individuals and approaches to previously immunized non-responders. In HEPATOLOGY
(Vol. 70, pp. 594A-594A). Hoboken, NJ: Wiley.
26. Yanny, B., El Kabany, M., & Saab, S. (2019, October). EIGHT WEEK HEPATITIS C VIRUS
TREATMENT WITH SOBOSFOVIR BASED REGIMEN IS EFFECTIVE IN PEOPLE WHO
INJECT DRUGS WITHIN 6 MONTHS OF TREATMENT DESPITE NON-ADHERENCE TO
LAB AND CLINIC FOLLOW-UP. In HEPATOLOGY (Vol. 70, pp. 956A-957A). Hoboken, NJ:
Wiley.
27. Saab, S. (2019). Portal Hypertension: Portal Hypertension (Vol. 23, No. 4). Elsevier Health
Sciences.
28. Hassanein, T. I. (2019). Hepatitis B Virus, An Issue of Clinics in Liver Disease (Vol. 23, No. 2).
Elsevier Health Sciences.
2020
29. Yanny, B., Boutros, S., Saleh, F., & Saab, S. (2020). Liver transplantation for alcoholic hepatitis:
update. Current Opinion in Gastroenterology, 36(3), 157-163.
30. Yanny, B., Pham, N. V., Saleh, H., & Saab, S. (2020). Approaches to assessing burden in
caregivers of patients with cirrhosis. Journal of Clinical and Translational Hepatology, 8(2), 127.
31. Yanny, B., Viramontes, M., Najarian, L. M., Challita, Y., & Saab, S. (2020). Ethnic perception of
obesity in fatty liver disease. Digestive Medicine Research, 3.
32. Grewal, J., Lenhart, A., Doan, A., Walter, K., Wang, Y., & Yanny, B. (2020). Su1664
POSITIVELY WRONG: NON-ALCOHOLIC STEATOHEPATITIS AND DRUG INDUCED
LIVER INJURY ARE ASSOCIATED WITH AUTOANTIBODY POSITIVITY IN PATIENTS
WITHOUT OTHER AUTOIMMUNE DISEASES IN A LARGE ACADEMIC SETTING.
Gastroenterology, 158(6), S-1379.
33. Lenhart, A., Grewal, J., Wang, Y., Kang, S., & Yanny, B. (2020). Sa1547 CHRONIC HEPATITIS
E POST-ORGAN TRANSPLANTATION CAN MIMIC REJECTION AND LEAD TO
CIRRHOSIS: A CASE SERIES EXPLORING PATIENT DEMOGRAPHICS, TREATMENT,
AND OUTCOMES. Gastroenterology, 158(6), S-1329.
34. Weiss, G. A. (2020). Diagnosis and Management of Gluten-Associated Disorders.
35. Yanny, B., Grewal, J. K., & Vaswani, V. K. (2020). Celiac Disease and the Liver. Diagnosis and
Management of Gluten-Associated Disorders: A Clinical Casebook, 27-40.
2022
36. Xu, H., & Yanny, B. (2022). Primary Biliary Cholangitis: A Review. Gene Expression, 21(2), 45-
50.
Yanny, Beshoy
Updated: July 2021
8
2023
37. Yanny, B., Alkhero, M., Alani, M., Stenberg, D., Saharan, A., & Saab, S. (2023). Post-COVID-19
cholangiopathy: a systematic review. Journal of Clinical and Experimental Hepatology, 13(3),
489-499.
38. Farooq, M., Irania, S., Bahdi, F., Yanny, B., & Issa, D. (2023). S2227 Bile Cast Syndrome in a
Young Female Following Severe COVID-19 Infection. Official journal of the American College of
Gastroenterology| ACG, 118(10S), S1596.
39. Nguyen, M., Yanny, B. T., Truong, T. L., Zhao, H., & Hanna, R. (2023). Tolvaptan-induced
isolated elevation of bilirubin in a patient with Gilbert syndrome. SAGE Open Medical Case
Reports, 11, 2050313X231169841.
40. Coe, C. L., Prause, N., Benhammou, J. N., Singh, J., Shetty, A., Trivedi, H., ... & Patel, A. A.
(2023, October). PREVALENCE AND PREDICTORS OF PROBLEMATIC ALCOHOL USE
AMONG TRANSPLANT HEPATOLOGISTS. In HEPATOLOGY (Vol. 78, pp. S1720-S1721).
Philadelphia, PA: Lippincott Williams & Wilkins.
2024
41. Singh, J., Ibrahim, B., Jackson, N. J., Khalil, H., Valenzuela, J., Yanny, B., & Saab, S. (2024).
Lower FIB-4 threshold in patients with diabetes improves diagnostic accuracy of the test in a
Hispanic population. Translational Gastroenterology and Hepatology, 9, 16.
42. Windheim, J., Yoon, S., Hahn, K., Klomhaus, A., Hixson, R., Wen, R., ... & Barjaktarevic, I.
(2024). THE ASSOCIATION OF ALPHA-1 ANTITRYPSIN LEVELS WITH LIVER
FUNCTION, AND THE CHANGE IN ALPHA-1 ANTITRYPSIN LEVELS
LONGITUDINALLY IN CIRRHOTIC PATIENTS. Chest, 166(4), A4893.
2025
43. Coe, C., Prause, N., Benhammou, J. N., Singh, J., Shetty, A., Trivedi, H. D., ... & Patel, A. A.
(2025). One in 4 transplant hepatologists in the United States screens positive for unhealthy
alcohol use. Hepatology Communications, 9(11), e0819.
Professional Societies
AASLD
ACG
Liver Health Foundation
Liver Wellness Foundation
Other Experience
Link to this profile
https://faculty.uci.edu/profile/?facultyId=7362
https://faculty.uci.edu/profile/?facultyId=7362
Last updated
03/16/2026
03/16/2026